July 11 (Reuters) - Mauna Kea Technologies SAS MKEA.PA :
* TASLY PHARMACEUTICALS AND MAUNA KEA TECHNOLOGIES ANNOUNCE
JOINT
VENTURE AND LICENSING AGREEMENTS
* SUBJECT TO TRANSFERRING IP ASSETS AND CONTRIBUTING
LICENSES TO
JV, MAUNA KEA TO RECEIVE 44% EQUITY INTEREST IN JOINT VENTURE,
CASH PAYMENTS TOTALING $10 MILLION, AND CELLVIZIO PURCHASING
COMMITMENTS FOR 5 YEARS
* JV ALSO TO ACQUIRE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP
AND
COMMERCIALIZE CELLVIZIO IN FIELDS OF NEUROLOGY AND NEUROSURGERY
Source text for Eikon: ID:nBwklCLTa
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))